Monoclonal Antibodies
Monoclonal Antibodies (mAbs) & Bispecifics
We profile your antibody therapeutics rigorously so you can confirm target binding, verify the intended immune response, and reduce the risk of off-target inflammation.
Binding & Specificity:
We screen your candidates using Sapidyne KinExa or flow cytometry to evaluate affinity across diverse cell panels.
Mechanism of Action (MoA) Assays:
Antibody-Dependent Cellular Cytotoxicity (ADCC) & Phagocytosis (ADCP):
We co-culture primary PBMCs or specific effector cells such as NK cells and macrophages with your target cells to quantify tumor killing or phagocytosis.
Complement-Dependent Cytotoxicity (CDC):
We measure complement cascade activation so you can understand whether your antibody drives target cell lysis.
Safety & Immunotoxicity:
We use cytokine release assays with human whole blood or PBMCs to assess cytokine storm risk before your first-in-human trials.
